Mayne Pharma Group (ASX:MYX) ROCE % : -12.05% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Mayne Pharma Group ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Mayne Pharma Group's annualized ROCE % for the quarter that ended in Dec. 2023 was -12.05%.

Mayne Pharma Group ROCE % Historical Data

The historical data trend for Mayne Pharma Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mayne Pharma Group ROCE % Chart

Mayne Pharma Group Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROCE %

Get a 7-Day Free Trial

-21.87

-6.88

-16.27

-19.36

-29.90

Mayne Pharma Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															-7.87	-28.58	-31.81	-20.03	-12.05

Mayne Pharma Group ROCE % Calculation

Mayne Pharma Group's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	-241.309	/	( ( (1287.926 - 610.421)	+	(1247.354 - 310.959) )	/ 2 )
	=	-241.309	/	( (677.505	+	936.395)	/ 2 )
	=	-241.309	/	806.95
	=	-29.90 %

Mayne Pharma Group's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-108.016	/	( ( (1247.354 - 310.959)	+	(1152.648 - 295.658) )	/ 2 )
	=	-108.016	/	( ( 936.395	+	856.99 )	/ 2 )
	=	-108.016	/	896.6925
	=	-12.05 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Mayne Pharma Group (ASX:MYX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Mayne Pharma Group ROCE % Related Terms

Thank you for viewing the detailed overview of Mayne Pharma Group's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mayne Pharma Group (ASX:MYX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mayne Pharma Group Ltd (ASX:MYX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

MAYNF:USA HG6:Germany

Address

1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106

Website

http://www.maynepharma.com

Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Branded Products (BPD) and Portfolio Products Division (PPD). The Portfolio Products Division distributes dermatology products (branded and generic) in the US on a portfolio basis, The Branded Products Division distributes branded women's health products in the US. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.